AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win

By /

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.

Scroll to Top